New technology

HEALTHPOINT® Creates HEALTHPOINT Surgical Division, Launches Oasis® Wound Matrix Product to New Markets

Concerns: technology
Released on: 02-Jan-2003

Pharmaceutical form and dosage: Biomaterial

Active substances / mechanism: Small intestinal submucosa, or SIS technology, on which Oasis is based, is extracted from the submucosal layer of porcine small intestines.

Type:

- Bio
- Curative
- Devices
- Drug delivery
- Pharmaceuticals / Therapeutics
- Prescription drugs (Rx)
- Preventive
- Technology

Therapeutic target:

- Aging
- Cancer
- Cardiovascular
- Dermatology
- Diabetes
- Gastrointestinal
- Infectious Diseases
- Men's Health
- Oncology
- Orthopedics
- Pain
- Surgery
- Transplant
- Urology
- Women's Health

Concerns the following market:
- United States of America

Full Description:
(Fort Worth, TX, USA) — H. Paul Dorman, President and CEO of HEALTHPOINT, Ltd., a Texas-based market leader in skin asepsis, tissue management, and dermatology products, has announced the formation of HEALTHPOINT Surgical, a new division of the company that will further expand infection prevention research, development, and product availability and launch one of HEALTHPOINT’s most innovative products, Oasis® Wound Matrix, to the surgical market.

The company’s former Infection Prevention division will be the foundation of HEALTHPOINT Surgical Division.

“HEALTHPOINT Surgical will leverage our core competencies in liquid/semi-solid formulation and manufacturing, dermatology drug actives, and acquisition/licensing depth for the future,” stated Mr. Dorman.

The new division will meet surgical marketplace demand for Oasis, an innovative biomaterial that provides a supportive environment to allow a patient’s body to heal itself. The product will now be marketed so that surgeons and other specialists will have access to this breakthrough technology, a natural, extracellular matrix that can manage a variety of wounds by helping the body rebuild and repair damaged tissue.

SIS Technology, on which Oasis is based, works by extracting a naturally derived, extracellular matrix material from the submucosal layer of porcine small intestines.

Since its inception in 1992, HEALTHPOINT has established a national presence in the research, development, and marketing of branded pharmaceuticals, over the counter drugs, and medical devices for the tissue management, dermatology, and surgical divisions. An aggressive research and development effort has brought HEALTHPOINT’s unique technologies to the market, setting the pace for its national field sales organization. HEALTHPOINT, with over 250 employees, is a DFB Pharmaceuticals, Inc. affiliate company.

HEALTHPOINT has an additional office in Canada. Visit HEALTHPOINT’s web site at www.healthpoint.com.

###

  Contact for this news release: Jay Nisbet